Sativex® (delta-9-tetrahydrocannibinol and cannabidiol in the EU) (nabiximols in the USA) Information Intended For
Healthcare Professionals

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Sativex® is an oromucosal spray of a formulated extract of the cannabis sativa plant that contains the principal cannabinoids delta-9-tetrahydrocannibinol (THC) and cannabidiol (CBD) in a 1:1 ratio as well as specific minor cannabinoids and other non-cannabinoid components. We developed Sativex® to be administered as an oromucosal spray, whereby the active ingredients are absorbed in the lining of the mouth, either under the tongue or inside the cheek. We have received regulatory approval for Sativex® in numerous countries outside the United States. In Europe, Sativex® has now received marketing authorization in 21 countries for the treatment of spasticity (muscle stiffness/spasm) due to MS.

GW does not market Sativex® directly. All requests for product information and adverse events reporting should be directed through the individual websites for the distributors listed in the HCP section.